Journal of Clinical Oncology

Recalibrating Digital Predictions: Uncovering the Limits of the MMAI Prostate LT-ADT Predictive Model in the Era of Tumor Evolution

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

PURPOSE The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [AT...

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy

Taletrectinib in ROS1 Fusion–Positive Non–Small Cell Lung Cancer: Promising Yet Premature?

Second Mitochondrial Activator of Caspases Mimetics Accelerate Progression of Locally Advanced Head and Neck Cancer

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

We report results of the final analysis of overall survival (OS) and patient-reported outcomes from the phase III KEYNOTE-585 (ClinicalTrials.gov identifier: NCT03221426...

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

PURPOSE Patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (epNETs) have limited systemic treatment options. Pazopanib, an oral multikinase inhibitor with ac...

Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

PURPOSE Human epidermal growth factor receptor 2 (HER2) amplification/overexpression (HER2-pos) is detected in 5% of RAS/BRAF wild-type metastati...

Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib

Brain Imaging Surveillance for Patients With Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice

KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?

Reply to: “Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib” and “Taletrectinib in ROS1 Fusion–Positive Non–Small Cell Lung Cancer: Promising Yet Premature?”

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)

PURPOSE WU-KONG1B (ClinicalTrials.gov identifier: NCT03974022 ) is a multinational phase II, dose-randomized stud...

Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study

PURPOSE TrilynX was a randomized, double-blind, phase III study evaluating the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) or placebo to chemoradiotherapy...

Reply to: Recalibrating Digital Predictions: Uncovering the Limits of the MMAI Prostate LT-ADT Predictive Model in the Era of Tumor Evolution